Business
Avacta (AVCT): Gearing up the management team
Avacta (AVCT): Gearing up the management team.
About this update from Avacta Group Plc
[{"type":"text","content":"\n \nHardman & Co ResearchHardman & Co Research: Avacta (AVCT): Gearing up the management team26-Jun-2018 / 13:30 GMT/BST\nHardman & Co Research: Gearing up the management team\n\nAvacta (AVCT) is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, which continues to dominate the drug industry, despite its limitations. The significant technical and commercial benefits of Affimers are being recognised through increased corporate interest, on-going evaluations, and deal flow. AVCT recently strengthened its board with the appointment of Eliot Forster, ex-Immunocore CEO, as non-executive Chairman. This move provides greater expertise in maximising the potential of the Affimers as a therapeutic platform.\n\nPlease click here for the full report:\n\nhttp://hardmanandco.com/docs/default-source/company-docs/avacta-documents/26.06.18-gearing-up-the-management-team.pdf \n\nTo contact us:Hardman & Co35 New Broad StreetLondonEC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCo\n Contacts:Dr Martin HallDr Dorothea HillDr Gregoire Pave+44 20 7194 7622\n [email protected]@[email protected]\n \n \n\nHardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.\n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.\n\nOur research is provided for the use of the ...